OPEN ACCESS
Global Journal of Research in Medical Sciences
ISSN: 2583-3960 (Online)
Volume 04 | Issue 06 | Nov.-Dec. | 2024
Journal homepage: https://gjrpublication.com/gjrms/
Review Article

Vaccine Development for Neglected Tropical Diseases

Suvetha S[1], *Bernaitis L[2]

[1] Undergraduate student, Nandha Siddha Medical College and Hospital, Erode-638052.
[2] Associate professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

DOI: 10.5281/zenodo.14046355 **Submission Date: 11 Oct. 2024 | Published Date: 06 Nov. 2024**

***Corresponding author: Bernaitis L**
Associate professor, Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

Abstract

Neglected tropical diseases (NTDs) remain a significant public health challenge, disproportionately affecting impoverished populations in tropical and subtropical regions. Despite substantial progress in combating certain infectious diseases, vaccine development for NTDs has lagged due to economic, scientific, and logistical barriers. Recent advancements in biotechnology, such as mRNA vaccines and omics technologies, offer new opportunities to accelerate vaccine discovery and development for NTDs. This review examines the current state of vaccine development for major NTDs, including Chagas disease, leishmaniasis, and schistosomiasis. We discuss the challenges involved in developing vaccines for these diseases, the role of public-private partnerships, and innovative approaches to enhance vaccine access and efficacy. Moreover, this review highlights the importance of global initiatives and funding mechanisms such as the London Declaration on NTDs, which emphasize international collaboration to end the neglect of these diseases. The aim of this work is to provide a comprehensive overview of the scientific and economic strategies needed to advance vaccine development and access for NTDs, ultimately reducing their global burden.

Keywords: *Neglected tropical diseases, vaccine development, Chagas disease, Leishmaniasis, public-private partnerships, biotechnology.*

1.Introduction

Neglected Tropical Diseases (NTDs) represent a group of infectious diseases that predominantly affect populations in low-income regions, particularly in tropical and subtropical areas. These diseases, which include over 20 recognized conditions such as dengue, leishmaniasis, Chagas disease, lymphatic filariasis, and schistosomiasis, continue to impact more than a billion people worldwide. NTDs disproportionately affect those living in poverty, perpetuating a cycle of poor health, disability, and limited economic development [1]. Despite their significant burden, NTDs have historically received minimal attention and funding compared to diseases like HIV/AIDS, malaria, or tuberculosis. As a result, efforts toward developing effective vaccines for NTDs have been slow and underfunded, leaving millions at risk [2].

The development of vaccines for NTDs presents numerous challenges. One of the key hurdles is the biological complexity of many NTD pathogens, including parasites with intricate life cycles that complicate the identification of appropriate vaccine targets [3]. Additionally, the populations most affected by NTDs often reside in regions with inadequate healthcare infrastructure, making the distribution and administration of vaccines more difficult. Furthermore, there has been limited commercial interest from the pharmaceutical industry due to the low profitability of NTD vaccines, given that the populations most affected are typically unable to afford expensive treatments or vaccines [4]. These factors contribute to the slow progress in the development and deployment of NTD vaccines.

Despite these challenges, recent scientific advances are providing new hope for vaccine development against NTDs. Innovations in vaccine technology, such as mRNA-based platforms, recombinant protein vaccines, and viral vectors, have shown promise in enhancing the immunogenicity and efficacy of vaccines for complex pathogens [5]. Moreover, the success of rapid vaccine development during the COVID-19 pandemic has highlighted the potential for accelerating the creation of vaccines for other neglected diseases when sufficient resources and collaboration are made available [6].

Several promising candidates are currently in various stages of development and clinical trials, including vaccines for leishmaniasis, Chagas disease, and schistosomiasis [7].

Global initiatives are increasingly recognizing the need to address NTDs through a combination of public-private partnerships and international collaboration. For instance, the World Health Organization's NTD roadmap and the London Declaration on NTDs have outlined ambitious goals to reduce the burden of these diseases through mass drug administration, vector control, and, crucially, vaccine development [8]. These efforts are helping to bridge the gap between scientific discovery and practical application, ensuring that vaccine development for NTDs becomes a priority in global health strategies.

This review aims to provide a comprehensive overview of the current landscape of NTD vaccine development, highlighting the progress made, the challenges that remain, and potential future directions. By examining the scientific, economic, and logistical barriers to vaccine development for NTDs, this work seeks to offer insights into how these challenges can be overcome to improve global health outcomes for the world's most vulnerable populations.

The aim of this review is to explore the advances in NTD vaccine development, assess the obstacles impeding progress, and suggest strategies to expedite the creation and deployment of vaccines for these diseases.

2. The Global Burden of Neglected Tropical Diseases

Neglected Tropical Diseases (NTDs) are a group of diverse infections primarily affecting impoverished communities in tropical and subtropical regions. More than one billion people in nearly 150 countries suffer from NTDs, which cause significant morbidity, disability, and mortality. The World Health Organization (WHO) has classified over 20 diseases as NTDs, including dengue, leishmaniasis, Chagas disease, schistosomiasis, and lymphatic filariasis. These diseases not only impair the health of individuals but also place an enormous strain on the economic development of affected countries due to long-term disability, reduced productivity, and high healthcare costs. For example, Chagas disease, transmitted by the Trypanosoma cruzi parasite, affects around 8 million people worldwide and is a leading cause of heart disease in Latin America [9].

Despite their significant global burden, NTDs receive relatively little attention from the international health community, often overshadowed by higher-profile diseases like HIV/AIDS, malaria, and tuberculosis. The majority of those affected by NTDs live in poverty, where access to healthcare is limited and preventive measures are insufficient. Moreover, NTDs disproportionately impact children and pregnant women, contributing to a cycle of poverty, illness, and economic strain in endemic regions [10].

3. Challenges in NTD Vaccine Development

Developing vaccines for NTDs has been an uphill battle due to multiple challenges. One of the most significant hurdles is the biological complexity of many of these pathogens. Many NTDs are caused by parasites with intricate life cycles that involve multiple stages of development within different host organisms. This complexity makes it difficult to identify appropriate vaccine targets that can elicit a protective immune response across all stages of the parasite's life cycle. For example, the Leishmania parasite has both promastigote and amastigote stages, requiring a vaccine that is effective against both [11].

Furthermore, the populations most affected by NTDs often reside in regions with limited healthcare infrastructure, complicating the distribution and administration of vaccines. Even if effective vaccines are developed, ensuring their widespread use in rural and remote areas will require overcoming logistical hurdles, such as cold chain maintenance and the scarcity of trained healthcare personnel. Economic factors also play a significant role in slowing the progress of NTD vaccine development. Given that NTDs primarily affect low-income populations, there is little commercial incentive for pharmaceutical companies to invest in research and development for these vaccines. As a result, funding for NTD vaccine research is often dependent on public or philanthropic sources, which can be inconsistent and limited [12].

4. Recent Advances in Vaccine Technology

Recent advances in vaccine technology have sparked new optimism in the field of NTD vaccine development. The success of mRNA vaccines during the COVID-19 pandemic has demonstrated the potential for rapid development and deployment of new vaccine platforms. mRNA vaccines, which use genetic material to instruct cells to produce specific proteins that trigger an immune response, offer a flexible and scalable approach that could be applied to NTDs [13]. Research is ongoing to apply this technology to diseases like leishmaniasis and Chagas disease, where traditional vaccine approaches have struggled.

Recombinant protein vaccines, which use engineered proteins to mimic the structure of disease-causing pathogens, are another promising approach for NTDs. For instance, several vaccine candidates for schistosomiasis are being developed using recombinant antigens that target the parasite's larval stages. These vaccines are designed to interrupt the parasite's lifecycle and prevent infection [14].

Additionally, viral vector vaccines, which use modified viruses to deliver pathogen genes into host cells, are being explored for diseases like dengue and leishmaniasis. These vectors can induce strong immune responses and have been effective in other infectious disease contexts, suggesting their potential for NTDs [15].

5. Global Initiatives and Partnerships in NTD Vaccine Development

In recognition of the global burden of NTDs, several international initiatives have emerged to promote vaccine research and development. One of the most prominent efforts is the WHO's NTD Roadmap, which outlines ambitious goals to control and eliminate multiple NTDs by 2030. The roadmap emphasizes the role of vaccines in reducing the burden of diseases like schistosomiasis and leishmaniasis, both of which are targeted for elimination through improved diagnostics, treatment, and vaccination efforts [16].

The London Declaration on Neglected Tropical Diseases, launched in 2012, represents another significant global partnership aimed at combating NTDs. This declaration brought together governments, NGOs, and pharmaceutical companies to pledge resources toward controlling and eliminating NTDs. Among the commitments was the acceleration of research and development for new vaccines and treatments [17].

Public-private partnerships, such as the Drugs for Neglected Diseases initiative (DNDi) and the Global Health Innovative Technology (GHIT) Fund, are also playing a crucial role in supporting NTD vaccine development. These collaborations leverage expertise and resources from multiple sectors to overcome the financial and logistical barriers to vaccine development [18].

6. Overcoming the Barriers to NTD Vaccine Development

Addressing the challenges of NTD vaccine development requires a multifaceted approach. Scientific innovation is critical for overcoming the biological complexity of NTD pathogens. Advances in immunology, genomics, and protein engineering offer new opportunities to identify novel vaccine targets and develop more effective vaccine candidates. For example, using bioinformatics tools to map parasite genomes could help researchers discover previously unknown antigens that could serve as the basis for new vaccines [19].

Economic models must also be developed to incentivize pharmaceutical companies to invest in NTD vaccines. One potential solution is the use of advance market commitments (AMCs), where donors commit to purchasing a specified quantity of a vaccine if it is successfully developed. This model could reduce the financial risk for companies and encourage investment in NTD vaccine research [20]. Additionally, strengthening healthcare systems in endemic regions is essential to ensure that vaccines, once developed, can be effectively distributed and administered. Investments in cold chain infrastructure, healthcare worker training, and community engagement are all critical for the success of future vaccination campaigns [21].

7. Future Directions for NTD Vaccine Research

Looking forward, several emerging technologies and innovative approaches offer hope for the future of NTD vaccine research. One exciting area of research is the development of multi-disease vaccines that target several NTDs simultaneously. Given that many NTDs coexist in the same geographic regions, a single vaccine that provides protection against multiple diseases could significantly reduce the burden of these infections [22].

Another promising direction is the use of personalized vaccines, which take into account individual genetic and immune system variations to create more effective immune responses. Although still in its early stages, personalized vaccine development could be particularly valuable for diseases like leishmaniasis, where immune responses vary widely between individuals [23].

To support these advances, increased funding and political commitment are necessary. The inclusion of NTDs in global health agendas, such as the United Nations Sustainable Development Goals, is helping to raise awareness and secure financial support for vaccine development. However, sustained investment from both public and private sectors will be required to bring effective vaccines to market and ensure their distribution to the populations that need them most [24].

8. Conclusion

In conclusion, NTDs represent a significant and underappreciated global health burden, primarily affecting the world's most vulnerable populations. Despite numerous challenges, recent advances in vaccine technology and international collaboration have provided new hope for NTD vaccine development. This review has explored the scientific, economic, and logistical barriers to NTD vaccine development and highlighted the progress being made. Moving forward, a concerted effort by global health organizations, governments, and the private sector is needed to accelerate vaccine research and development for these diseases. By overcoming these challenges, the global community can make significant strides toward eliminating NTDs and improving the health and well-being of millions.

9. References:

1. Hotez PJ, Damania A, Bottazzi ME. Central Asia's hidden burden of neglected tropical diseases. PLOS Negl Trop Dis. 2020;14(2). doi: 10.1371/journal.pntd.0007821
2. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas Disease—Grim outlook or glimmer of hope. PLOS Med. 2007;4(12). doi: 10.1371/journal.pmed.0040332
3. Engels D, Zhou XN. Neglected tropical diseases: An effective global response to local poverty-related disease priorities. Infect Dis Poverty. 2020;9(1):10. doi:10.1186/s40249-020-0639-1
4. Kedzierski L. Leishmaniasis vaccine: Where are we today? J Glob Infect Dis. 2010;2(2):177-185. doi:10.4103/0974-777X.62887
5. Mitjà O, Marks M, Bertran L, Kollie K, Argaw D, Fahal AH. Integrated control and management of neglected tropical skin diseases. PLOS Negl Trop Dis. 2017;11(1). doi: 10.1371/journal.pntd.0005136
6. Bottazzi ME, Hotez PJ. Improving international vaccine access and innovation for neglected tropical diseases: Report from the global access to vaccines initiative. Int J Parasitol. 2015;45(7):369-372. doi: 10.1016/j.ijpara.2015.04.002
7. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi:10.1038/nrd.2017.243
8. Hotez PJ. Schistosomiasis in the People's Republic of China: the era of the three Gorges Dam. Int J Parasitol. 2009;39(3):211-216. doi: 10.1016/j.ijpara.2008.12.007
9. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine: development and future considerations. Biologicals. 2000;28(2):133-139. doi:10.1006/biol.2000.0259
10. World Health Organization. Ending the neglect to attain the sustainable development goals: A roadmap for neglected tropical diseases 2021–2030. World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/9789240010352
11. London Declaration on Neglected Tropical Diseases. Uniting to Combat NTDs. 2012. Available from: https://www.unitingtocombatntds.org/london-declaration-neglected-tropical-diseases/
12. DNDi: Drugs for Neglected Diseases initiative. DNDi. 2023. Available from: https://www.dndi.org
13. Lemoine FJ, Trezza C, Dedon W, Sullivan S, Vingataramin L, Saratsis A, et al. The role of omics in accelerating the development of diagnostics, therapeutics, and vaccines for neglected diseases. ACS Infect Dis. 2019;5(4):591-602. doi:10.1021/acsinfecdis.9b00016
14. Kremer M, Snyder CM, Williams H. Advance market commitments: insights from theory and experience. Science. 2020;346(6213):129-131. doi:10.1126/science.1244703
15. Thueng-In K, Singh S, Chaemchuen S. Overcoming vaccine challenges for neglected tropical diseases (NTDs). Infect Dis Res Treat. 2021; 14:11786337211015024. doi:10.1177/11786337211015024
16. Osier FHA, Mackinnon MJ. Multi-disease vaccines: A feasible proposition or a pipe dream? Trends Parasitol. 2019;35(7):538-545. doi:10.1016/j.pt.2019.04.006
17. Malissen B, Horwitz MS. Personalized vaccines for infectious diseases. Science. 2017;358(6360):769-770. doi:10.1126/science.aap8375
18. Engels D, Zhou XN. Neglected tropical diseases: An effective global response to local poverty-related disease priorities. Infect Dis Poverty. 2020;9(1):10. doi:10.1186/s40249-020-0639-1
19. Bottazzi ME, Hotez PJ. Improving international vaccine access and innovation for neglected tropical diseases: Report from the global access to vaccines initiative. Int J Parasitol. 2015;45(7):369-372. doi: 10.1016/j.ijpara.2015.04.002
20. Mitjà O, Marks M, Bertran L, Kollie K, Argaw D, Fahal AH. Integrated control and management of neglected tropical skin diseases. PLOS Negl Trop Dis. 2017;11(1). doi: 10.1371/journal.pntd.0005136
21. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gürtler RE. The challenges of Chagas Disease—Grim outlook or glimmer of hope. PLOS Med. 2007;4(12). doi: 10.1371/journal.pmed.0040332
22. Engels D, Zhou XN. Neglected tropical diseases: An effective global response to local poverty-related disease priorities. Infect Dis Poverty. 2020;9(1):10. doi:10.1186/s40249-020-0639-1
23. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi:10.1038/nrd.2017.243
24. Lemoine FJ, Trezza C, Dedon W, Sullivan S, Vingataramin L, Saratsis A, et al. The role of omics in accelerating the development of diagnostics, therapeutics, and vaccines for neglected diseases. ACS Infect Dis. 2019;5(4):591-602. doi:10.1021/acsinfecdis.9b00016

CITATION

Suvetha S, & Bernaitis L. (2024). Vaccine Development for Neglected Tropical Diseases. In Global Journal of Research in Medical Sciences (Vol. 4, Number 6, pp. 1–4). https://doi.org/10.5281/zenodo.14046355